David Avigan, M.D.

Dr. Avigan is Assistant Professor of Medicine, Harvard Medical School, aand Director of Hematological Malignancies and Bone Marrow Transplantation, Beth Israel Deaconess Medical Center and Dana Farber Harvard Cancer Center, Boston, MA.

Within the last 12 months Dr. Avigan reports research support from Genzyme and Berlex.

This activity is made possible by an unrestricted educational grant from .

Release Date: 12/06/2007
Termination Date: 02/19/2010

Estimated time to complete: 1 hour(s).

Albert Einstein College of Medicine designates this enduring material for a maximum of 0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Upon completion of this Cyberounds^®, the participant should be able to:

• Identify the unique biological characteristics of AML in the elderly and their impact on response to therapy
• Discuss therapeutic trials in elderly patients with AML which examine the role of aggressive and low intensity chemotherapy
• Define the role of autologous and allogeneic hematopoietic transplantation in elderly patients with AML
• Discuss the role of novel agents as therapy for elderly patients with AML.

 

This conference may include discussion of commercial products and services.

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

 

Please click below to accept the terms of this CME activity